Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Improvements in survival among cancer patients have revealed the clinical impact of
cardiotoxicity on both cardiovascular and hematological and oncological outcomes …

Background Several studies have investigated the effect of non–vitamin K antagonist oral
anticoagulants (NOAC s) in atrial fibrillation (AF) patients with cancer, but the results remain …

Patients with brain tumors are at high risk for thromboembolic complications and frequently
require anticoagulation. Direct oral anticoagulants (DOACs) are a less burdensome …

Prescription of anticoagulants (ACs) in patients with cancer and atrial fibrillation (AF) is
challenging and the impact on survival is not defined. In this study data prospectively …

Cardiology and oncology are two fields dedicated to the study of various types of
oncological and cardiac diseases, but when they collide, a new specialty is born, ie, cardio …

Hypertension is one of the most common comorbidities in cancer patients with malignancy,
in particular, in the elderly. On the other hand, hypertension is a long-term consequence of …

Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are
among the recommended treatment options for cancer-associated thrombosis (CAT) in the …

Background To evaluate the efficacy and safety of different direct oral anticoagulants
(DOACs) compared with low molecular weight heparins (LMWHs) in the treatment of venous …

Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered
and raises critical problems that often result in serious morbidity or mortality. Most cardiac …